Dietrich CG, Gartung C, Lorenzen J, Geier A, Wasmuth HE, Matern S, Lammert F

Language: English
References: 11
Page: 118-120
PDF size: 31.70 Kb.

Text Extraction

We describe the case of a 36-years-old male patient, originating from India, who presented with enlarged cervical lymph nodes and elevated liver chemistry tests. Histologically necrosing granulomas were observed in the lymph nodes, and PCR revealed DNA from mycobacterium tuberculosis. However, in the liver biopsy granulomatous hepatitis without central necrosis was seen. With a positive PCR for mycobacteria from liver tissue and no evidence for other hepatic diseases we started drug treatment with standard quadruple regimen consisting of isoniazid, rifampicin, ethambutol, and pyrazinamide. Five days after onset of therapy, liver chemistry tests rose 10-fold, forcing us to interrupt treatment. Gradual step-wise re-exposition with the same medication after return of liver chemistry tests to baseline was well tolerated without any further side effects. Liver involvement of tuberculosis can have many facets and may be treated by gradual dosing of standard drugs.

REFERENCES

1. Chen HC, Chao YC, Shyu RY, Hsieh TY. Isolated tuberculous liver abscesses with multiple hyperechoic masses on ultrasound: a case report and review of the literature. Liver International 2003; 23: 346-50.

2. Gaya DR, Thorburn D, Oien KA, Morris AJ, Stanley AJ. Hepatic granulomas: a 10 year single centre experience. Journal of Clinical Pathology 2003; 56: 850-3.

3. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.[see comment]. American Journal of Respiratory & Critical Care Medicine 2003; 167: 1472-7.

4. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antituberculotic medicines and assessment of risk factors. Ann Pharmacother 2004; 38: 1074-1079.

5. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-30.

6. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-9.

7. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, Majumder PP. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation. Journal of Gastroenterology & Hepatology 2001; 16: 1033-7.

8. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status. Drug Safety 1996; 15: 394-405.

9. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy. Clinical profile and reintroduction of therapy. Journal of Clinical Gastroenterology 1996; 22: 211-4.

10. Tahaoglu K, Atac G, Sevim T, Tarun T, Yazicioglu O, Horzum G, Gemci I, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. International Journal of Tuberculosis & Lung Disease 2001; 5: 65-9.

11. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-48.